文献速递系统性红斑狼疮

干扰素相关生物标志物监测SLE疾病活动度的纵向基准研究

Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该前瞻性纵向研究纳入26例SLE患者共77次访视,比较3种IFN相关标志物与6种传统标志物同BILAG 2004疾病活动度的相关性,并用ROC与Youden指数确定纵向阈值及精度。IP-10、SIGLEC1和ANuA升高最能反映复发,抗dsDNA(ELISA)、IFNα和抗dsDNA(Farr法)下降最能反映缓解。

要点

  • IP-10、SIGLEC1和ANuA升高对SLE复发具有较高特异性,可作为监测疾病活动的候选标志物。
  • 抗dsDNA(ELISA)、IFNα和抗dsDNA(Farr法)下降最能反映缓解,敏感性75%、62%和75%。
  • 该研究首次给出SLE纵向生物标志物阈值及复发与缓解的判断精度。

核心结论

  • IP-10、SIGLEC1和ANuA在监测SLE疾病活动度方面具有优势,该研究首次提供纵向生物标志物阈值及复发与缓解的判断精度。

研究设计与样本

  • 前瞻性纵向研究,纳入26例SLE患者共77次访视,比较3种IFN相关标志物与6种传统标志物和BILAG 2004疾病活动度的相关性。
  • 用ROC曲线与Youden指数确定各标志物的最佳纵向上下阈值及其反映复发与缓解的准确性。

主要发现

  • IP-10升高超过纵向上限阈值101.6 pg/ml反映复发,敏感性50%、特异性95%。
  • SIGLEC1升高超过纵向上限阈值5.01相对平均荧光强度反映复发,敏感性83%、特异性90%。
  • ANuA升高超过纵向上限阈值16.20 IU/ml反映复发,敏感性58%、特异性95%。
  • 抗dsDNA(ELISA)下降至纵向下限阈值以下64.7 IU/ml反映缓解,敏感性75%、特异性95%。
  • IFNα下降至纵向下限阈值以下16.69 pg/ml、抗dsDNA(Farr法)下降至纵向下限阈值以下3.3 IU/ml反映缓解,敏感性分别为62%和75%,特异性分别为90%和90%。

关键数值与推荐

  • 复发判断:IP-10升高>101.6 pg/ml(敏感性50%、特异性95%),SIGLEC1升高>5.01相对平均荧光强度(83%、90%),ANuA升高>16.20 IU/ml(58%、95%)。
  • 缓解判断:抗dsDNA(ELISA)下降>64.7 IU/ml(75%、95%),IFNα下降>16.69 pg/ml(62%、90%),抗dsDNA(Farr法)下降>3.3 IU/ml(75%、90%)。

临床怎么用

  • 可将IP-10、SIGLEC1和ANuA的纵向阈值用于辅助判断SLE复发,将抗dsDNA(ELISA)、IFNα和抗dsDNA(Farr法)的下降用于辅助判断缓解。
  • 在IFN靶向治疗背景下,趋化因子和基于流式细胞术的IFN标志物用于监测SLE活动度值得进一步研究。

局限性

  • 样本量较小(26例患者、77次访视),阈值与精度的外推需谨慎。
  • 研究仅基于BILAG 2004指数评估疾病活动度,结论在其他活动度评估体系下的适用性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the clinical value of six traditional and three IFN-related biomarkers in monitoring disease activity (DA) in SLE. METHODS: Prospective longitudinal study of IFNα, IFNγ-inducible protein 10 (IP-10) and sialic acid-binding Ig-like lectin 1 (SIGLEC1) vs antibodies against dsDNA (ELISA and Farr radioimmunoassay), dsDNA-complexed nucleosomes (anti-dsDNA-NcX: ELISA), nucleosomes (ANuA: ELISA) and complement C3/C4 for correlation with DA (measured by BILAG 2004 index) in 26 SLE patients (77 visits). Optimal upper and lower longitudinal thresholds for the biomarkers and their accuracies for reflecting clinically relevant changes in DA (flares and remission) were determined by receiver operating characteristic and Youden index analysis. RESULTS: Increases in IP-10, SIGLEC1 and ANuA to + 101.6 pg/ml, +5.01 relative mean fluorescence intensity and +16.20 IU/ml above the calculated upper longitudinal threshold significantly reflected lupus flares, with a sensitivity and specificity of 50 and 95% for IP-10, 83 and 90% for SIGLEC1 and 58 and 95% for ANuA. Decreases in anti-dsDNA (ELISA), IFNα and anti-dsDNA (Farr assay) to - 64.7 IU/ml, -16.69 pg/ml and -3.3 IU/ml below lower longitudinal thresholds, respectively, best reflected remission, with sensitivity and specificity of 75 and 95%, 62 and 90%, and 75 and 90%, respectively. CONCLUSION: IP-10, SIGLEC1 and ANuA emerged as advantageous biomarkers for monitoring disease activity. This is the first study in SLE that provides longitudinal biomarker thresholds and test accuracies for SLE flares and remitting disease. In the context of IFN-directed therapies, chemokines and fluorescence-activated cell sorting-based IFN biomarkers for monitoring SLE activity should be further studied.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rose T, Grützkau A, Klotsche J, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology (Oxford). 2017. PMID: 28859328. doi:10.1093/rheumatology/kex220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。